Cargando…
Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice
Biosimilars that were not compared in clinical trials with the compound innovator are not true biosimilars (biocopies) and are associated with risks that the clinical rheumatologist should be aware of before generalized use. This article comments on various aspects surrounding the use of such biocop...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336503/ https://www.ncbi.nlm.nih.gov/pubmed/25677586 http://dx.doi.org/10.1186/s13075-014-0501-5 |